Advertisement

Clinical Reviews in Allergy & Immunology

, Volume 45, Issue 1, pp 47–62 | Cite as

Pathogenic Intracellular and Autoimmune Mechanisms in Urticaria and Angioedema

  • Katherine Altman
  • Christopher Chang
Article

Abstract

Urticaria and angioedema are common disorders. Chronic urticaria is defined as lasting longer than 6 weeks. Causes of chronic urticaria fall into the following categories: physical, allergic, hereditary, autoimmune, and idiopathic. Basophils and mast cells are the primary effector cells responsible for clinical symptoms and signs. These cells produce and secrete a variety of mediators including histamine, leukotrienes, prostaglandins, cytokines, chemokines, and other pro-inflammatory mediators. This leads to vasodilation, fluid exudation, increased vascular permeability, and accumulation of additional secondary inflammatory cells. Two mechanisms have been investigated as possibly contributing to the pathogenesis of chronic urticaria. One is the development of autoantibodies to FcεRI or IgE on mast cells and basophils. This appears to be responsible for 30–50 % of cases. The other is dysregulation of intracellular signaling pathways involving Syk, SHIP-1, or SHIP-2 in basophils and mast cells. The primary treatment for chronic urticaria is to treat the underlying pathology, if any can be identified. Otherwise, in idiopathic cases, H1 antihistamines, H2 antihistamines, antileukotrienes, and corticosteroids constitute the main pharmacologic treatment modalities. In severe and recalcitrant cases of chronic and autoimmune urticaria, immunosuppressive drugs have been used, most commonly cyclosporin. More recent experimental studies have also suggested that omalizumab, an anti-IgE therapy, may be of benefit. Currently, inhibitors of Syk are also being developed and tested in the laboratory and in animal models. As our understanding of the pathogenesis of idiopathic urticaria increases, development of additional drugs targeting these pathways may provide relief for the significant physical and psychological morbidity experienced by patients with this disorder.

Keywords

Angioedema Autoimmune Basophil FcεRI Histamine IgE Leukotriene Mast cell Omalizumab Syk Urticaria 

References

  1. 1.
    Greaves MW, Tan KT (2007) Chronic urticaria: recent advances. Clin Rev Allergy Immunol 33:134–143PubMedCrossRefGoogle Scholar
  2. 2.
    Guldbakke KK, Khachemoune A (2007) Etiology, classification, and treatment of urticaria. Cutis 79:41–49PubMedGoogle Scholar
  3. 3.
    Saini SS (2009) Basophil responsiveness in chronic urticaria. Curr Allergy Asthm Rep 9:286–290CrossRefGoogle Scholar
  4. 4.
    Crivellato E, Ribatti D (2010) The mast cell: an evolutionary perspective. Biol Rev 85:347–360PubMedCrossRefGoogle Scholar
  5. 5.
    Zhang M, Murphy RF, Agrawal DK (2007) Decoding IgE Fc receptors. Immunol Res 37:1–16PubMedCrossRefGoogle Scholar
  6. 6.
    Ali H (2010) Regulation of human mast cell and basophil function by anaphylatoxins C3a and C5a. Immunol Lett 128:36–45PubMedCrossRefGoogle Scholar
  7. 7.
    Kaplan AP, Greaves M (2009) Pathogenesis of chronic urticaria. Clin Exp Allergy 39:777–787PubMedCrossRefGoogle Scholar
  8. 8.
    Siracusa MC, Comeau MR, Artis D (2011) New insights into basophil biology: initiators, regulators, and effectors of type 2 inflammation. Ann NY Acad Sci 1217:166–177PubMedCrossRefGoogle Scholar
  9. 9.
    Falcone FH, Knol EF, Gibbs BF (2011) The role of basophils in the pathogenesis of allergic disease. Clin Exp Allergy 41:939–947PubMedCrossRefGoogle Scholar
  10. 10.
    Siraganian RP, de Castro RO, Barbu EA, Zhang J (2010) Mast cell signaling: the role of protein tyrosine kinase Syk, its activation and screening methods for new pathway participants. FEBS Lett 584:4933–4940PubMedCrossRefGoogle Scholar
  11. 11.
    Bugajev V, Bambouskova M, Draberova L, Draber P (2010) What precedes the initial tyrosine phosphorylation of the high affinity IgE receptor in antigen-activated mast cell? FEBS Lett 584:4949–4955PubMedCrossRefGoogle Scholar
  12. 12.
    Yamasaki S, Saito T (2008) Progress in allergy signal research on mast cells: signal regulation of multiple mast cell responses through FcεRI. J Pharmacol Sci 106:336–340PubMedCrossRefGoogle Scholar
  13. 13.
    Saini SS, Paterniti M, Vasagar K, Gibbons SP, Sterba PM, Vonakis BM (2009) Cultured peripheral blood mast cells from chronic idiopathic urticaria patients spontaneously degranulate upon IgE sensitization: relationship to expression of Syk and SHIP-2. Clin Immunol 132:342–348PubMedCrossRefGoogle Scholar
  14. 14.
    Vonakis BM, Gibbons S, Sora R, Langdon JM, MacDonald SM (2001) Src homology 2 domain-containing inositol 5′ phosphatase is negatively associated with histamine release to human recombinant histamine-releasing factor in human basophils. J Allergy Clin Immunol 108:822–831PubMedCrossRefGoogle Scholar
  15. 15.
    Vonakis BM, Vasagar K, Gibbons SP et al (2007) Basophil FcεRI histamine release parallels expression of Src-homology 2-containing inositol phosphatases in chronic idiopathic urticaria. J Allergy Clin Immunol 119:441–448PubMedCrossRefGoogle Scholar
  16. 16.
    Vasagar K, Vonakis BM, Gober LM, Viksman A, Gibbons SP, Saini SS (2006) Evidence of in vivo basophil activation in chronic idiopathic urticaria. Clin Exper Allergy 36:770–776CrossRefGoogle Scholar
  17. 17.
    Lezhoff A, Jasse RG, Denburg J, Dolovich J (1983) Association of chronic urticaria and angioedema with thyroid autoimmunity. Arch Dermatol 119:636–640CrossRefGoogle Scholar
  18. 18.
    Gruber BL, Baeza ML, Marchese MJ, Agnello V, Kaplan AP (1988) Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol 90:213–217PubMedCrossRefGoogle Scholar
  19. 19.
    Hide M, Francis DM, Grattan C, Hakimi J, Kochan JP, Greaves MW (1993) Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 328:1599–1604PubMedCrossRefGoogle Scholar
  20. 20.
    Fiebiger E, Maurer D, Holub H et al (1995) Serum IgG autoantibodies directed against the α chain of FcεRI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? J Clin Invest 96:2606–2612PubMedCrossRefGoogle Scholar
  21. 21.
    Fiebiger E, Hammerschmid F, Stingl G, Mauere D (1998) Anti-FcεRIα autoantibodies in autoimmune-mediated disorders: identification of a structure–function relationship. J Clin Invest 101:243–251PubMedCrossRefGoogle Scholar
  22. 22.
    Sabroe RA, Fiebiger E, Francis DM et al (2002) Classification of anti-FcεRIα and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity. J Allergy Clin Immunol 110:492–499PubMedCrossRefGoogle Scholar
  23. 23.
    Mozena JD, Tinana A, Negri J, Steinke JW, Borish L (2010) Lack of a role for cross-reacting anti-thyroid antibodies in chronic idiopathic urticaria. J Invest Dermatol 130:1860–1865PubMedCrossRefGoogle Scholar
  24. 24.
    Platzer MH, Grattan CEH, Poulsen LK, Skov PS (2005) Validation of basophil histamine release against the autologous serum skin test and outcome of serum-induced basophil histamine release studies in a large population of chronic urticaria patients. Allergy 60:1152–1156PubMedCrossRefGoogle Scholar
  25. 25.
    Alyasin S, Hamidi M, Karimi AA, Amiri A, Ghaffarpasand F, Ehsaei MJ (2011) Correlation between clinical findings and results of autologous serum skin test in patients with chronic idiopathic urticaria. Southern Med J 104:111–115PubMedCrossRefGoogle Scholar
  26. 26.
    Kulthanan K, Jiamton S, Gorvanich T, Pinkaew S (2006) Autologous serum skin test in chronic idiopathic urticaria: prevalence, correlation and clinical implications. Asian Pac J Allergy Immunol 24:201–206PubMedGoogle Scholar
  27. 27.
    Khalaf AT, Li W, Jinquan T (2008) Current advances in the management of urticaria. Arch Immunol Ther Exp 56:103–114CrossRefGoogle Scholar
  28. 28.
    Zuberbier T, Maurer M (2007) Urticaria: current opinions about etiology, diagnosis and therapy. Acta Derm Venereol 87:196–205PubMedGoogle Scholar
  29. 29.
    Belsito DV (2010) Second-generation antihistamines for the treatment of chronic idiopathic urticaria. J Drugs Dermatol 9:503–512PubMedGoogle Scholar
  30. 30.
    Kapp A, Pichler WJ (2006) Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, parallel, multicenter study. Int J Dermatol 45:469–474PubMedCrossRefGoogle Scholar
  31. 31.
    Nettis E, Colanardi MC, Barra L, Ferrannini A, Vacca A, Tursi A (2006) Levocetirizine in the treatment of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Brit J Dermatol 154:533–538CrossRefGoogle Scholar
  32. 32.
    Staeveska M, Popov TA, Kralimarkova T et al (2010) The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol 125:676–682CrossRefGoogle Scholar
  33. 33.
    Hong JB, Lee HC, Hu FC, Chu CY (2010) A randomized, double-blind, active-controlled, parallel-group pilot study to compare the efficacy and sedative effects of desloratadine 5 mg with levocetirizine 5 mg in the treatment of chronic idiopathic urticaria [letter]. J Am Acad Dermatol 63:e100–e102PubMedCrossRefGoogle Scholar
  34. 34.
    Watson NT, Weiss EL, Harter PM (2000) Famotidine in the treatment of acute urticaria. Clin Dermatol 25:186–190CrossRefGoogle Scholar
  35. 35.
    Moscati RM, Moore GP (1990) Comparison of cimetidine and diphenhydramine in the treatment of acute urticaria. Ann Emerg Med 19:12–15PubMedCrossRefGoogle Scholar
  36. 36.
    Runge JW, Martinez JC, Caravati EM, Williamson SG, Hartsell SC (1992) Histamine antagonists in the treatment of acute allergic reactions. Ann Emerg Med 21:237–242PubMedCrossRefGoogle Scholar
  37. 37.
    Nettis E, D’Erasmo M, Di Leo E et al (2010) The employment of leukotriene antagonists in cutaneous diseases belonging to allergological field. Mediat Inflamm 2010:1–6CrossRefGoogle Scholar
  38. 38.
    Drazen JM, Israel E, O’Bryne PM (1999) Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 340:197–206PubMedCrossRefGoogle Scholar
  39. 39.
    Pacor ML, Di Lorenzo G, Corrocher R (2001) Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additives and/or acetylsalicylic acid. Clin Exper Allergy 31:1607–1614CrossRefGoogle Scholar
  40. 40.
    Nettis E, Dambra P, D’Oronzio L, Loria MP, Ferrannini A, Tursi BA (2001) Comparison of montelukast and fexofenadine for chronic idiopathic urticaria. Clin Exp Dermatol 27:29–31CrossRefGoogle Scholar
  41. 41.
    Erbagci Z (2002) The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study. J Allergy Clin Immunol 110:484–488PubMedCrossRefGoogle Scholar
  42. 42.
    Nettis E, Colanardi MC, Paradiso MT, Ferrannini A (2004) Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy 34:1401–1407PubMedCrossRefGoogle Scholar
  43. 43.
    Di Lorenzo G, Pacor ML, Mansueto P et al (2004) Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol 114:619–625PubMedCrossRefGoogle Scholar
  44. 44.
    Asero R, Tedeschi A (2010) Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria: a retrospective analysis. J Investig Allergol Clin Immunol 2:386–390Google Scholar
  45. 45.
    Grattan CEH, O’Donnell BF, Francis DM et al (2000) Randomized double-blind study of cyclosporin in chronic ‘idiopathic’ urticaria. Brit J Dermatol 143:365–372CrossRefGoogle Scholar
  46. 46.
    Barlow RJ, Black AK, Greaves MW (1993) Treatment of severe, chronic urticaria with cyclosporin A. Eur J Dermatol 3:273–275Google Scholar
  47. 47.
    Toubi E, Blant A, Kessel A, Golan TD (1997) Low dose cyclosporin A in treatment of severe chronic idiopathic urticaria. Allergy 52:312–316PubMedCrossRefGoogle Scholar
  48. 48.
    Daher N, Lieberman P (2010) Immunosuppression medication as an approach to treat chronic urticaria in children. Curr Allergy Asthma Rep 10:1–2PubMedCrossRefGoogle Scholar
  49. 49.
    Perez A, Woods A, Grattan CEH (2009) Methotrexate: a useful steroid-sparing agent in recalcitrant chronic urticaria. Brit J Dermatol 162:191–194CrossRefGoogle Scholar
  50. 50.
    McGirt LY, Vasagar K, Gober LM, Saini SS, Beck LA (2006) Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine. Arch Dermatol 142:1337–1342PubMedCrossRefGoogle Scholar
  51. 51.
    Reeves GEM, Boyle MJ, Bonfield J, Dobson P, Loewenthal M (2004) Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation. Intern Med J 34:182–186PubMedCrossRefGoogle Scholar
  52. 52.
    Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK (2008) Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 122:569–573PubMedCrossRefGoogle Scholar
  53. 53.
    Spector SL, Tan RA (2007) Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 99:190–193PubMedCrossRefGoogle Scholar
  54. 54.
    Saavedra MC, Sur S (2011) Down regulation of the high-affinity IgE receptor associated with successful treatment of chronic idiopathic urticaria with omalizumab. Clin Mol Allergy 9:2PubMedCrossRefGoogle Scholar
  55. 55.
    Boers M (2011) Syk kinase inhibitors for rheumatoid arthritis: trials and tribulations. Arthritis Rheum 63:329–330PubMedCrossRefGoogle Scholar
  56. 56.
    Scott DL (2011) Role of spleen tyrosine kinase inhibitors in management of rheumatoid arthritis. Drugs 71:1121–1132PubMedCrossRefGoogle Scholar
  57. 57.
    Riccaboni M, Bianchi I, Petrillo P (2010) Spleen tyrosine kinases: biology, therapeutic targets and drugs. Drug Discov Today 15:517–530PubMedCrossRefGoogle Scholar
  58. 58.
    Mazuc E, Villoutreix BO, Malbec O et al (2008) A novel drug-like spleen tyrosine kinase binder prevents anaphylactic shock when administered orally. J Allergy Clin Immunol 122:188–194PubMedCrossRefGoogle Scholar
  59. 59.
    Villoutreix BO, Laconde G, Lagorce D, Martineau P, Miteva MA, Dariavach P (2011) Tyrosine kinase syk non-enzymatic inhibitors and potential anti-allergic drug-like compounds discovered by virtual and in vitro screening. PLoS One 6:e21117PubMedCrossRefGoogle Scholar
  60. 60.
    Roquedes-Contios AM, Misery L (2011) What is intrinsic atopic dermatitis. Clin Rev Allergy Immunol 41:233–236CrossRefGoogle Scholar
  61. 61.
    Liu FT, Goodarzi H, Chen HY (2011) IgE, mast cells, eosinophils and atopic dermatitis. Clin Rev Allergy Immunol 41:298–310PubMedCrossRefGoogle Scholar
  62. 62.
    Misery L (2011) Therapeutic perspectives in atopic dermatitis. Clin Rev Allergy Immunol 41:267–271PubMedCrossRefGoogle Scholar
  63. 63.
    Di Lorenzo G, Leto-Barone MS, La Piana S, Seidita A, Rini GB (2012) Chronic spontaneous urticaria: an autoimmune disease? A revision of the literature. Clin Exp Med. doi: 10:1007/s10238-012-0188-3, E-pub ahead of print

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Division of Allergy, Asthma and ImmunologyThomas Jefferson University, Nemours/AI duPont Hospital for ChildrenWilmingtonUSA
  2. 2.SeattleUSA

Personalised recommendations